A video on how Kids v Cancer is creating incentives and requirements for companies to undertake pediatric studies. more→
How the RACE for Children Act will get drugs to kids with cancer (The Cancer Letter, by Nancy Goodman)
Taken together, the RACE for Children Act and the Pediatric PRV program change the landscape of pediatric cancer research. more→
RACE for Children Act is law (KVC Newsletter)
The RACE for Children Act became law, ensuring that novel and exciting new cancer drugs will now be developed not only for adults, but also for children with cancer. more→
Everything you need to know about FDA’s Priority Review Vouchers (RAPS Regulatory Explainer)
What are the Priority Review Vouchers and how do they benefit the society? more→
Children with cancer get more access to experimental drugs (Science)
The Research to Accelerate Cures and Equity for Children (RACE) Act will close loopholes in U.S. drug approval guidelines that companies have exploited to avoid enrolling children in clinical cancer research. more→
Don’t leave them waiting: How to bring new cancer drugs to kids (Morning Consult, by Elena Gerasimov)
The RACE Act is needed because most kids with cancer are treated with medicines from the time when my mom was young. more→
RACE for Children Act seeks to boost childhood cancer research (Life Science Daily)
Current law does not reflect advances in cancer drug development because these therapies have been under-studied in pediatric cancer. more→
Kids v. Cancer advocates for RACE for Children Act (CNBC)
Nancy Goodman, Kids v. Cancer founder, discusses her push for the development of pediatric cancer drugs. With CNBC’s Meg Tirrell.
Kids v Cancer Pediatric Cancer Legislative Yearbook 2016
The Pediatric Cancer Legislative Yearbook 2016 summarizes the achievements of pediatric cancer advocacy organizations and outlines next steps for 2017. more→
Enrolling adolescents in disease/target-appropriate adult oncology clinical trials of investigational agents (Clinical Cancer Research)
The paper recommends the inclusion of adolescents (ages 12-17) in disease- and target-appropriate adult oncology trials. more→
Creating Hope Act reauthorized in 21st Century Cures (KVC Newsletter)
On December 13, 2016, President Obama signed into law the 21st Century Cures Act, reauthorizing the Creating Hope Act until 2020. more→
Too many PD-1 trials for adults, too few for children (The Cancer Letter, by Nancy Goodman)
Why are there so few trials for which children and young teens would qualify? Shouldn’t kids and teens also get a shot at exciting investigational drugs? more→
How one drug company fast-tracked the FDA’s review process (PBS News Hour)
A voucher program shaves months off of the FDA’s review process for drug development that targets rare pediatric diseases. more→
Nature supports RACE for Children Act
Kids v Cancer welcomes NATURE’s editorial in support of the RACE for Children Act to champion the development of promising cancer drugs for children. more→
Fairer way to distribute last-ditch drugs gets real-world trial (Nature Magazine)
Drug companies’ compassionate policies hard to decipher, and experts are testing what they hope is a fairer system to distribute drugs. more→